Recent findings suggest a promising connection between GLP-1 medications and lower risks of certain cancers, particularly as the availability and affordability of these treatments improve across Canada. As semaglutide and its generics become more widely accessible, researchers presented compelling data at the American Society of Clinical Oncology meeting in Chicago, indicating that patients using GLP-1 drugs may experience not only a lower incidence of cancer but also enhanced survival rates and improved treatment responses.
Groundbreaking Research Highlights Cancer Prevention Potential
The research presented at the conference included over two dozen studies, with many indicating substantial benefits for patients using GLP-1 medications. Dr. Judith Bray, Vice-President of Research at the Canadian Cancer Society, remarked on the transformative potential of these findings, noting, “These rumbling or smoking guns have been firing off for well over a year now about this possibility, so all of a sudden, the whole research world woke up.”
One notable study published in the ESMO Annals of Oncology analysed data from more than 161,000 patients, predominantly aged around 47, who were either obese or overweight but had not been diagnosed with diabetes or obesity-related cancers. Half of the participants received weight-loss injections, while the other half followed standard diet and exercise consultations. The results revealed that those on GLP-1 medications had a striking 41 per cent lower likelihood of being diagnosed with an obesity-related cancer over a two-year follow-up period.
Insights into GLP-1 Drugs and Breast Cancer
In a separate study conducted by JCO Oncology Practice, researchers examined the relationship between GLP-1 treatment and breast cancer incidence. They found that GLP-1 therapy was associated with a lower occurrence of breast cancer, regardless of age, race, ethnicity, BMI, or diabetes status. The study tracked over 110,000 women aged 45 to 80 who underwent breast imaging between January 2022 and June 2025. Of those, nearly 14 per cent were prescribed GLP-1 drugs.
The study’s findings were significant: women taking these medications exhibited up to a 35 per cent reduced risk of developing breast cancer. Further analysis matched over 15,000 women on GLP-1 medication with similar non-users, confirming nearly a 31 per cent lower risk among those on the treatment. Lead researcher Dr. Elizabeth McDonald emphasised that while the study is observational and does not definitively prove a direct link between GLP-1 medications and reduced breast cancer risk, it certainly merits further investigation into the role of these weight-loss drugs in cancer prevention.
Call for Canadian Research
Breast cancer is projected to be the most commonly diagnosed cancer among women in Canada by 2026, making these findings even more critical. Kimberly Carson, CEO of Breast Cancer Canada, expressed optimism about the research, describing it as “very encouraging” and highlighting the importance of further investigation. “I really love the progress that we’re making here,” she stated, underscoring the need for Canadian studies to explore the potential of GLP-1 medications in cancer prevention.
“We’re not looking at any Canadian data yet, and I think we do have the capacity to run a study like this in Canada,” Carson added. “There’s an opportunity for Canada to contribute significantly to this burgeoning field of research.”
Why it Matters
The implications of these findings are profound, particularly in a healthcare landscape increasingly focused on preventative measures. With obesity rates rising sharply in Canada—68 per cent of adults aged 18 to 79 are now classified as overweight or obese, up from 60 per cent before the pandemic—innovative approaches to cancer prevention are urgently needed. The potential of GLP-1 medications to serve as both weight-loss treatments and cancer-prevention tools could revolutionise public health strategies, offering hope to millions at risk. As research continues to unfold, the intersection of diabetes management and cancer prevention may well open new avenues for treatment and patient care, transforming lives and healthcare outcomes across the nation.
